ESR1 and neoplasm: Additionally, decreased expression levels of FTO combined with a high degree of reader proteins YTHDF1 и IGF2BP3 in clinical NSCLC tissues promote tumor progression, metastasis, and drug resistance by regulating the ESR1 transcript, which activates proliferative signaling cascades and provides resistance to endocrine therapies through ERα pathway initiation [33].